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Abstract   
 
Objective: To determine incidence and patterns of natural course of ecstasy/stimulant/hallucinogen 
(ESH) use and disorders as well as cohort effects in a community sample of adolescents and young 
adults. Method: Cumulative incidence and patterns of ecstasy use and disorders were examined in a 
prospective longitudinal design (mean follow-up period=42 months) in a representative sample 
(N=2446) aged 14–24 years at the outset of the study. Patterns of DSM-IV defined ESH use, abuse 
and dependence were assessed with the Munich Composite International Diagnostic Interview (M-
CIDI). Results: (1) Cumulative lifetime incidence for use of ESH at second follow-up: 9.1%, 1.0% for 
abuse, 0.6% for dependence; (2) men used and abused ESH more often than women; (3) the younger 
birth cohort (1977–81) tended to start earlier with substance (ab)use compared to the older birth cohort 
(1970–77); (4) use of ESH was associated with increasing rates of concomitant use of other licit and 
illicit drugs; (5) the majority of the lifetime ESH users without disorder had stopped to use these 
substances and not consumed them during the 12 months preceding the second follow-up; (6) those 
who had stopped to take ecstasy and related drugs at follow-up also took other illicit drugs less often 
than those who continued to consume ESH. Conclusions: Use of designer drugs is widespread in our 
sample, but the probability of developing use disorders is fairly low (1.6%). The majority of the ESH 
users stopped their use spontaneously in their twenties (80% of the prior users without disorder, 67% 
of the prior abusers), but 50% of those that once had fulfilled DSM-IV criteria of dependence 
continued to use these substances.    
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1. Introduction  
 
New synthetic ‘designer’ drugs are becoming increasingly popular among adolescents and 
young adults, especially ecstasy (mostly taken as a tablet which contains amphetamine 
derivates, especially MDMA but as well MDE or MDA) (Pederson and Skrondal, 1999).  
 
In scientific as well as in popular texts there is a great controversy if ecstasy is a relatively 
benign (and even psychotherapeutically effective) substance (Szukaj, 1994) or a dangerous 
neurotoxin (McCann et al., 1998). There is also a lack of knowledge concerning the incidence 
and prevalence of ecstasy use and use disorders in the general population. Research deficits 
are mainly due to the fact that ecstasy studies mostly have highly selected samples (Cohen, 
1996; Fischer, 2000; Green et al., 1995; Jansen, 1999; McGuire et al., 1994; Schifano, 2000; 
Thomasius, 2000), usually do not have prospective longitudinal designs, do not use specified 
diagnostic criteria for clinically relevant abuse or dependence patterns and focus on the 
initiation of ecstasy use, not on its reduction or cessation.  
 
Studies with selected samples of ecstasy users or patients reveal that ecstasy users are 
polydrug users who reveal increased levels of psychopathology and suffer relatively often 
from slight cognitive impairment (Andresen et al., 2000; Parrott et al., 2000; Schifano et al., 
1998; Schuetz et al., submitted, Thomasius, 2000; Topp et al., 1999; Tossmann, 1997).  
 
Epidemiological studies about the use of ecstasy and related substances reveal that the 
lifetime-incidence of ecstasy use varied in European students aged 13–18 years in the mid-90s 
between 0% (e.g. Finland) and 8–12% (UK); it was 1% in Canada and 2% in the USA 
(Kokkevi et al., 2000a; Capsules, 1993; Pederson and Skrondal, 1999; Smart and Ogborne, 
2000). In university students the variation is even higher: the lifetime use of ecstasy or 
‘designer drugs’ is 1.6% in Spain (Martinez et al., 1999), 13% in the UK (Webb et al., 1996) 
and it had been 39% at Stanford University during the early 80s (Peroutka et al., 1987). In 
representative community samples of adolescents and adults in Europe the lifetime use varies 
between 0.2% (Greece) and 4.5% (Spain) (Christophersen, 2000; de la Fuente et al., 1997; 
EMCDDA, 1998; Kokkevi et al., 2000b). In Germany-West 1.7% of the population have tried 
designer drugs and of the 21–24-year-olds 6.5% have used amphetamins and 5.7% ecstasy 
(Kraus and Bauernfeind, 1998; Kraus et al., 1998).  
 
Males report a 2–3-times higher lifetime use than females do (de la Fuente et al., 1997; 
Pederson and Skrondal, 1999). It seems that ecstasy is most popular in northern and central 
Europe (UK, Germany) and is becoming increasingly popular in the U.S. and Canada. The 
comparison of historical trends across various studies and countries is hampered by the fact 
that most studies do not refer to the concept of ‘cohort’ (a group defined by calendar year(s) 
of birth; Neugarten and Datan, 1973) and do not present the years of birth of their study 
participants.  
 
To date, no representative population-based data are available concerning the prevalence of 
abuse and dependence of ecstasy except for preliminary results from our EDSP study (see 
below).  
 
While there is a continuing discussion going on whether cannabis use is a transitional 
phenomenon in adolescence and young adulthood (Perkonigg et al., 1999; Sydow et al., in 
press), this discussion has not even been started with regard to ecstasy because there is a lack 
of prospective-longitudinal studies on that issue. But because ecstasy use is associated with a 
certain youth subculture (techno, rave parties) one can as well speculate if its use is a ‘youth-
limited’ transitional or a permanent phenomenon. Therefore, it is a question of vital 
importance whether ecstasy users also tend to stop their drug consumption spontaneously in 
their 20s like about 50–60% of the cannabis users do (Chen and Kandel, 1998; Hammer and 
Vaglum, 1990; Johnston et al., 1992; Kandel and Faust, 1975; Kandel and Logan, 1984; 
Silbereisen, 1997; Sydow et al., in press) or whether they continue to use the drug over longer 
periods. Even more so since it seems that the cumulative lifetime dose of consumed ecstasy is 
related to neurological impairments (McCann et al., 1998; Thomasius, 2000).  
 
It has also been shown that—at least in non-representative samples—ecstasy use is associated 
with increasing risks to use other illicit drugs, such as amphetamines, hallucinogens, 
stimulants and opiates (Parrott et al., 2000; Schifano et al., 1998; Solowij et al., 1992; 
Thomasius, 2000; Topp et al., 1999; Tossmann, 1997). Therefore, it is important to evaluate if 
ex-ecstasy users who have stopped taking the drug compensate their ecstasy-abstinence with 
an increased consumption of other licit or illicit drugs.  
 
The Early Developmental Stages of Psychopathology study (EDSP; Wittchen et al., 1998b; 
Lieb et al., 2000), a prospective-longitudinal community-study, examined the natural course 
of ecstasy (and related drugs) use in a representative sample of 14–24-year-olds in Munich, 
Germany. Ecstasy use results from the EDSP-baseline and 20 months prospective data for the 
younger cohort (initially aged 14–17 years) have already been presented. We have 
demonstrated that 1995 4% of the 14–24-year-old males and 2.3% of the females in Munich 
had tried ecstasy. The younger birth cohort started earlier and used ecstasy more often when 
compared to the older cohort. 0.8% fulfilled DSM-IV criteria for ecstasy (and related 
substances) use disorders. At baseline, almost one third of the lifetime consumers of ecstasy 
and related drugs had already stopped using these drugs—often motivated by fear of 
performance and health impairments (Schuster et al., 1998; Schuster and Wittchen, 1996). 
Further, it was demonstrated that consumers of ecstasy and related substances use illicit and 
licit drugs more often than other people, suffer more often from various mental disorders 
(abuse/dependence of alcohol, nicotine, illicit drugs; anxiety disorders; affective disorders; 
suicidal ideation; number of DSM-IV diagnoses) than those who do not use illicit drugs or 
those who take other illicit drugs (mostly cannabis) and visit mental health services more 
often. In 80% of the non-drug related disorders the participants stated that the mental disorder 
started before the ecstasy use was started (Schuetz et al., submitted).  
 
The focus of this paper is to describe the natural course of use, abuse and dependence of 
ecstasy and related drugs (stimulants, hallucinogens) over a period of 4 years in a German 
sample of adolescents and young adults, aged 14–24 at baseline and 17–28 at follow-up (birth 
cohorts 1970–1981), highlighting gender, age and cohort effects. The following questions will 
be examined:  
 
1. What is the age of onset of ecstasy/stimulant/hallucinogen use?  
2. How prevalent is ecstasy/stimulant/hallucinogen use in adolescence and young adulthood?  
3. How prevalent is ecstasy/stimulant/hallucinogen abuse and dependence according to DSM-
IV criteria?  
4. How stable are the patterns of ecstasy/stimulant/hallucinogen use, abuse and dependence 
across time, with emphasis on increases, reductions and spontaneous remissions?  
5. Is the cessation of ecstasy/stimulant/hallucinogen use accompanied by a compensative 
increase in the use of other drugs or by a decrease?  
 
2. Method  
 
2.1. Design  
 
The Early Developmental Stages of Psychopathology study (EDSP) (Wittchen et al., 1998b; 
Lieb et al., 2000) explores the prevalence, incidence, comorbidity, risk factors, protective 
factors and the 4-year course of mental disorders, with specific emphasis on substance- use 
disorders in a representative general population sample. The study is divided into three waves, 
spanning from 1995 (t0) to 1998–99 (t2).  
 
2.2. Baseline sample and follow-up investigations  
 
The sample was drawn randomly from the 1994 government registries of residents in 
metropolitan Munich. A total of 3021 participants aged 14–24 years (birth cohorts 1970–
1981) were successfully interviewed at baseline, resulting in a response rate of 71%. Since the 
study was designed with a special interest in early stages of substance use disorders, 14–15-
year-olds were sampled at twice the probability of 16–21-year-olds, and 22–24-year-olds 
were sampled at half the probability. At baseline, almost threequarters of the participants were 
students, 36% at the secondary level and 26% at university, and 20% of the participants were 
employed. Nearly two-thirds (62%) were living with their parents, 23% were living alone, and 
12% were living with their partner/spouse. The majority of the respondents were classified as 
middle class (59%), reflecting the population of Munich.  
 
Two follow-up investigations were completed after the initial baseline assessment, covering 
an overall period of 42 months (range: 34–50 months). The first follow-up (t1) was conducted 
in 1996/1997 and confined to the younger subsample (aged 14–17 at baseline); 1228 
interviews were completed, giving a follow-up response rate of 88%. The second follow-up 
(t2) included all baseline respondents and was conducted in 1998–99, an average of 42 
months after the baseline investigation (range 34–50 months); the response rate was 83% 
(N=2548). Of these, 102 participants did not want to respond to questions about illicit drug 
use at t0, t1 or t2. Therefore, our dataset is N=2446 with regard to the longitudinal 
development of drug use/abuse across 3.5 years: 1101 participants in the younger cohort 
(aged 14–17 at baseline, born between 1977–1981), and 1345 in the older cohort (aged 18–24 
at baseline, born between 1970– 1977). Data from all three assessments are used in this paper. 
Noteworthy changes in sociodemographic characteristics from baseline to second follow-up 
were only found for school/employment status (t2: secondary school: 13%, employed: 36%) 
and living arrangements (with parents: 40%; with partner: 23%).  
 
2.3. Measures  
 
Face-to-face computer-assisted interviews were administered by professional health 
interviewers and clinical psychologists at baseline and at the two follow- ups. Diagnostic 
assessments (t0–t1–t2) were based on the Munich version of the Composite International 
Diagnostic Interview (M-CIDI; Wittchen and Pfister, 1997). At baseline, lifetime and past 12 
month substance-use, substance use disorders and other mental disorders were assessed 
according to DSM-IV criteria. In both follow-up investigations, substance use and diagnoses 
during the follow-up period(s) and for the previous 12 months were evaluated. The MCIDI is 
an updated version of the World Health Organization’s CIDI version 1.2 (WHO-CIDI; World 
Health Organization, 1990), which incorporates questions to cover DSM-IV (American 
Psychiatric Association, 1994) and ICD-10 criteria. The reliability and procedural validity of 
the M-CIDI has been established (Lachner et al., 1998; Reed et al., 1998; Wittchen et al., 
1998a).  
 
Ecstasy use, abuse and dependence was assessed within the M-CIDI module L (illegal 
substances). Because ecstasy is pharmacologically related to amphetamines, as well as to 
hallucinogens and because ecstasy-pills often contain not only MMDA but as well other 
amphetamine derivates (Galliot-Guilley et al., 1999), ecstasy use was assessed in the context 
of two substance groups, namely group 2 ‘stimulants and related substances’ (amphetamine, 
speed, ecstasy etc.) and group 7 ‘hallucinogens’ (ecstasy, LSD, mescaline etc.). Therefore, our 
ecstasy-related results refer to those participants who stated that they either have taken 
stimulants (including ecstasy) or hallucinogens, specifically ecstasy; but frequency data 
always refer to both groups of substances (stimulants and hallucinogens), i.e., to ecstasy and 
related substances (see Schuster and Wittchen, 1996).  
 
2.4. Data analysis  
 
In line with the WHO-CIDI conventions (WHO 1990; Lachner et al., 1998), four mutually 
exclusive patterns of drug use were considered (never; one time; 2–4 times; five or more 
times). Additionally, the category of the ‘5+ times’ users was subdivided into those with 
‘considerable’ use (participant never consumed the relevant drug(s) more than two times 
during 1 week) or ‘heavy’ use (participant consumed substance(s) at least three times during 1 
week) according to their peak ecstasy-use-per-week period. At second follow-up, the 
cumulative lifetime consumption of ecstasy and related substances was assessed: those 
subjects classified as having a ‘considerable’ lifetime use on average had consumed 
ecstasy/stimulants/hallucinogens 5–12 times (29.2%) or 13–50 times (25.0%; no information: 
43.1%; N=72) and those classified as having a ‘heavy’ lifetime use actually had an use 
between 51–100 times (30.3%), 101–150 times (15.2%), 151–200 times (3.0%), 201–365 
(12.1%) and > 356 times (6.1%; no information: 33.3%).  
 
Lifetime prevalence at baseline denotes the rate of occurrence of a use pattern in the total 
sample or subsamples, and it covers the respondents’ lifetime period prior to the assessment at 
baseline. Follow-up incidence of substance (ab)use was defined as new outcomes during the 
follow-up period (t0–t2) among nonusers at baseline. Cumulative lifetime incidence was 
calculated by adding baseline, t1 and t2 follow-up incident cases. Twelve-month prevalence 
rates at follow-up refer to the prevalence of drug use, abuse or dependence during the year 
preceding the t2-follow-up interview.  
 
To account for different sampling probabilities for the different age-groups, non-contact and -
response, all measures were estimated using weighted data. To account for design effects 
introduced by the use of weighted data, statistical inference was performed using the software 
package STATA (StataCorp, 1999) that applies the Huber–White sandwich matrix in this case 
(Royall, 1986). Survival analyses were used for the examination of age of onset data.  
 
Age-specific cumulative lifetime incidences for ecstasy/ stimulant/hallucinogen use, abuse 
and dependence were estimated with the Kaplan-Meier method (Andersen and Keiding, 
1996). Differences between curves were assessed with hazard ratios (HR) from the Cox 
proportional hazards model. The proportional hazards assumption, i.e., hazard ratios being 
independent of age, was tested with so-called Schoenfeld residuals (Grambsch and Therneau, 
1994). When this assumption was violated for cohort differences, a stratified Cox model was 
used, i.e. different curves in age-cohorts were fitted before testing for group differences 
(Andersen and Keiding, 1996). In the case that the assumption was violated for gender 
differences the interaction term female gender x age was added to the model to test whether 
age is differently associated with the outcome for females as compared to males. A hazard 
ratio smaller than one then means that women have an earlier onset, conditional on the event 
that the outcome event is given.  
 
3. Results  
 
3.1. What is the age of onset of ecstasy/stimulant/hallucinogen use?  
 
Fig. 1 shows the age-specific cumulative lifetime incidences for use of 
ecstasy/stimulants/hallucinogens by gender and birth cohort. First use was rarely reported 
before the age of 14. But afterwards, there was a steep increase in use which stagnated at age 
24 for females and 26 for males.  
 
Group differences in age of onset according to gender and birth cohort were analyzed with 
hazard ratios (HR). Cohort differences could only be analyzed for the period 0–21 years, the 
highest age reached by members of the younger cohort. With regard to use of ecstasy and 
related substances we found a significant cohort difference (HR=0.25, 95% confidence 
interval/CI=0.15– 0.41, P<0.05) as well as a gender effect (HR=0.58, CI=0.36–0.92, P<0.05; 
the proportional hazards assumption was not violated; Cox model stratified for year of birth). 
While fewer females then males started to use ecstasy and related drugs, of those who did, 
more girls started at an earlier age. The curve showing the increase of ecstasy use was steeper 
for the younger cohort than for the older group (Fig. 1).  
 
3.2. How prevalent is ecstasy/stimulant/hallucinogen use in adolescence and young 
adulthood?  
 
At baseline, 95.3% of the sample had never used ecstasy/stimulants/hallucinogens, 1.1% 
reported having used such a drug on a single occasion, 1.2% reported use ‘2–4 times’, 2.0% 
reported a ‘considerable’ and 0.4% a ‘heavy use’ (see Table 1). The cumulative lifetime 
incidence by the second follow-up, roughly 4 years later, revealed a decrease in the proportion 
of subjects with no ecstasy use ever (90.9%), and an increase in the proportion of 5+ users 
(‘considerable use’: 4.1%; ‘heavy use’ 0.7%). Of the baseline non-users, 95.4% remained 
abstinent while 4.6% started using ecstasy and related drugs during the follow-up period; 
there were almost equal proportions of new users with rare use (one time: 1.2%; 2–4 times: 
1.3%) and with regular use (‘considerable’: 1.8%; ‘heavy’: 0.3%). Taking the follow-up (t2 ) 
12 -month prevalence as a rough measure for outcome and particular discontinuation, the 
fourth column of Table 1 reveals that only 2.8% of the entire sample had used ecstasy and 
related drugs during the year preceding the second follow-up, indicating that two thirds of all 
lifetime users had stopped their use during the previous 12 months.  
 
Regardless of the time interval researched, men always described a slightly higher use of the 
drugs in question than women (OR=1.2–1.5). But this did only reach significance when risk 
for use was compared to non-use with regard to the cumulative lifetime incidence at the 
second follow-up (OR=1.4, 95% CI=1.0–1.9, P<0.05).  
 
With regard to the risk for use versus non-use the older cohort had higher ecstasy use at 
baseline (OR= 3.9, CI=2.1–7.2, P<0.05), but with regard to cumulative lifetime incidence at 
follow-up, there were no significant cohort differences (OR=0.9, CI=.7–1.2). Concerning all 
other follow-up data (incidence among baseline non-users: OR=0.3, CI=0.2–0.5, P<0.05; 12-
month follow-up prevalence: OR=0.5, CI=0.3– 0.9, P0.05; follow-up prevalence: OR=0.5, 
CI= 0.3–0.7, P<0.05), there is a reversed effect: the younger cohort consistently had a higher 
risk of using ecstasy and related substances.  
 
3.3. How prevalent is ecstasy/stimulant/hallucinogen abuse and dependence?  
 
Rates of DSM-IV-defined ecstasy/stimulant/hallucinogen abuse and dependence at baseline 
and follow-up are shown in Table 2. At baseline, 0.5% of the sample fulfilled criteria for 
abuse (without dependence), and 0.4% for dependence. The cumulative lifetime incidence at 
follow-up (t2 ) reveals an increase with rates of 1.0% for abuse and 0.6% for dependence. The 
follow-up incidences among baseline non-users were low (abuse: 0.4%; dependence: 0.2%), 
as were follow-up (t2 ) 12-month prevalences (abuse: 0.3%; dependence: 0.04%).  
 
With one exception (risk of dependence at baseline) men generally had a slightly higher risk 
of developing ecstasy abuse and dependence. But results did only reach significance for the 
risk of abuse or dependence as compared to use without disorder with regard to follow-up 
cumulative lifetime incidence (OR=2.8, CI=1.2–6.8, P<0.05). With regard to the follow-up 
12-month-prevalence this could not be assessed for the risk of dependence as compared to 
non-dependence because there were no female dependent participants.  
 
We did not find any significant cohort difference with regard to fulfilling criteria for DSM-IV 
defined ecstasy/ stimulant/hallucinogen use disorders. But again, this could not be assessed 
for dependence at follow-up 12-month-prevalence because there were no dependent 
participants in this interval coming from the younger subgroup.  
 
3.4. How stable are the patterns of ecstasy/stimulant/hallucinogen use, abuse and dependence 
across time?  
 
Tables 3 and 4 report the findings on change over time in use of ecstasy and related 
substances by cross-tabulating cumulative lifetime incidence (assessed 12 months prior the 
second follow-up) and 12-months follow-up findings along with the estimated conditional 
probabilities (%) for four use patterns (no use, 1–4 times use, considerable use, heavy use; 
Table 3) and for four abuse patterns (no use, use without disorder, abuse without dependence, 
dependence; Table 4). In Table 3, a general tendency for stopping the use of ecstasy and 
related substances becomes visible: 99.2% of the prior abstinent participants remained 
abstinent, 87.7% of the prior 1–4 time users did not use these substances in the year preceding 
the second follow-up, as did 64.6% of those with a prior considerable use and 72.5% of those 
with a prior heavy use. This tendency can be found in both cohorts and both genders (When 
comparing the subgroups we did not find any non-overlapping confidence intervals which 
indicates that there are no significant cohort or gender differences; see Table 3).  
 
With regard to abuse patterns (Table 4) a similar tendency appears: ecstasy users without a 
disorder tended to become non-users (79.8%). About 80% of those diagnosed as having had 
an ecstasy/stimulant/hallucinogen abuse had improved during the 12-months follow-up 
interval—mostly by becoming non-users (67.2%), less often by becoming users without 
disorder (14.9%); 17.9% remained abusers and none developed dependence. Of those with an 
initial (cumulative lifetime) dependence, 6.7% remained dependent, 7.5% moved to abuse 
without dependence, while half of this group showed total remission to no-use (50.0%) and 
35.8% showed partial improvement to use without disorder. Again, we did not find any 
significant cohort or gender effects.   
 
3.5. Is the cessation of ecstasy/stimulant use accompanied by a compensative increase in the 
use of other drugs or by a decrease?  
 
Finally, it is important to assess whether ecstasy-abstinence in former consumers of ecstasy 
and related substances is compensated by increased levels of consumption of other illicit and 
licit drugs (Table 5). Ex-users of ecstasy/stimulants still consume more often nicotine (68.6 
vs. 36.1%), cannabis (58.8 vs. 21.0%), sedatives (3.6 vs. 0.4%), cocaine (15.2 vs. 1.1%), 
hallucinogens (7.6 vs. 0.3%) and opiates (4.3 vs. 0.6%) when compared to those participants 
who have never used ecstasy and related drugs. But in the year before the second follow-up, 
ex-users have consumed other illicit drugs significantly less often than continuous users of 
ecstasy and related drugs did. This is the case with cannabis (58.8 vs. 83.6%), cocaine (15.2 
vs. 71.5%), hallucinogens (7.6 vs. 37.0%) and inhalants (0.3 vs. 5.0%).  
 
 
 
4. Discussion  
 
In this paper data on the natural course of use, abuse and dependence of ecstasy and related 
substances (stimulants, hallucinogens) over 4 years are presented, from a prospective-
longitudinal representative community sample of 2446 German adolescents, aged 14–24 at 
baseline and 17–28 at the second follow-up. Data was collected in personal interviews with an 
established reliable and valid standardized, computerized instrument (M-CIDI) (Wittchen and 
Pfister, 1997; Reed et al., 1998; Wittchen et al., 1998a). This study is the first to explore the 
longitudinal development of use and abuse of ecstasy and related substances in a 
representative community sample.  
 
4.1. Limitations of the study  
 
Some limitations of the study should be considered:  
 
1. Due to the fact that self-report data on the use of ecstasy, stimulants and hallucinogens are 
imprecise and might not reflect the pharmacological ingredients, we decided to lump them 
together in most of the analyses. This is also in line with the observation that many consumers 
indicated that they have used these types of drugs anyhow (Schuetz et al., submitted).  
2. Interpretation of some of the analyses for abuse and dependence of ecstasy and related 
drugs is hampered by the fact that relatively few cases developed a disorder.  
3. Some attrition occurred from baseline to t2-followup that might have had an effect on the 
data. For example, users of any illicit drugs and participants with drug use disorders had a 
slightly but non-significant higher probability of not participating at the second follow-up 
(OR=1.5–1.7). Further, 102 participants of the study did not want to answer to questions 
about illicit drug use at one or more of the assessments. This potential selective attrition might 
have resulted in the description of a too favorable pattern of ecstasy/stimulant/hallucinogen 
use, abuse and dependence.  
4. Complexity of the field work resulted in a relatively variable follow-up length (range: 34–
50 months). Therefore, follow-up incidence data are reduced in their precision because they 
refer to varying time-intervals.  
 
4.2. Prevalence of use and disorders of ecstasy and related substances in Germany  
 
The overall cumulative lifetime incidence rate of 9.1% for use of ecstasy and related drugs 
(stimulants, hallucinogens) at the second follow-up for our then 17–28- year-old participants 
is higher than those found in other representative community samples. Kraus et al. (1998) 
described that 5.7% of West-German 21–24- year-olds have tried ecstasy and 6.5% 
amphetamines. In Spain, 5.7% of the 20–24-year-olds have ever have used designer drugs (de 
la Fuente et al., 1997). This might not necessarily mean that our cohorts consume such drugs 
more frequently but might also be related to the wider range of drugs taken into account in our 
study. Yet our findings are comparable to the higher estimates of adolescents’ and young 
adults’ ecstasy use in Europe, stemming from the UK (8–12%: Smart and Ogborne, 2000). In 
countries at the periphery of Europe (Finland, Czech Republic, Norway, Greece: 0–3%) and 
in the US and Canada (1–2%), ecstasy seems to be distinctly less popular (de la Fuente et al., 
1997; Kokkevi et al., 2000b; NIDA, 1993; Pederson and Skrondal, 1999; Smart and Ogborne, 
2000).  
 
As most other researchers have reported, we also found that men use ecstasy and related 
substances more often than women do, although the gender difference is in our data less 
pronounced (10.8 males vs. 7.6% females ever had used ecstasy and related substances at 
second follow-up) than the 3:1 ratio in Spain or the 2:1 ratio in Norway (de la Fuente et al., 
1997; Pederson and Skrondal, 1999).  
 
4.3. Use of ecstasy and related drugs—a transient phase-specific phenomenon?  
 
The proportions of subjects who had stopped using these substances even after prolonged and 
heavy use in the course of our study is substantial. Our follow-up outcome analyses reveal 
that 88% of subjects with previous occasional use (1–4 times) of ecstasy and related drugs 
were found to be non-users in the 12 months preceding the second follow-up. Among those 
subjects that had previously been diagnosed as having had a DSM-IV diagnosis of 
ecstasy/stimulant/hallucinogen abuse, 67% reported no use of such drugs at follow-up. Only 
those persons previously classified as dependent were less likely to have stopped their drug 
use during the 12 months preceding the second follow-up: 50% stopped to use these 
substances and half continued (36% use, no disorder; 8% abuse; 7% dependence).  
 
These discontinuation rates for ecstasy and related drugs are actually higher that those 
established for cannabis in our study. For example, only 54.7% of the prior cannabis users 
without disorder stopped to take cannabis over 4 years in our study, only 13.8% of the prior 
abusers and only 16.2% of those formerly classified as cannabis dependent (Sydow et al., in 
press). In each of these categories a higher percentage of ecstasy users stopped to use the 
drug(s) entirely (79.8, 67.2, 50.0%). We currently explore in additional analyses which factors 
are responsible for the higher discontinuation rates among ecstasy users focusing on the 
effects of costs for drugs, their availability as well as different attitudes to their use, 
particularly focusing on harmful health effects.  
 
Overall, ages 16–23 were found to be the peak hazard ages for initiation of 
ecstasy/stimulant/hallucinogen use. Our considerably higher cumulative incidence data 
assessed at the second follow-up (t2) for CIDI-DSM-IV defined abuse (1.0%) and dependence 
(0.6%) from ecstasy and related substances in 17–28-year-olds cannot be compared to other 
data because such have not yet been published from other researchers.  
 
It is remarkable that we found substantial birth cohort differences in previous analyses 
(Sydow et al., in press), with regard to the longitudinal pattern of cannabis use (the older 
cohort, born 1970–77, stopped cannabis use more often than the younger cohort, born 1977–
81)— but not with regard to the use of ecstasy and related substances. Both cohorts showed 
the same pattern of stopping drug use. Our findings suggest: (1) that ecstasy use is usually 
initiated between 16 and 23 years of age; (2) the majority of users of ecstasy and related drugs 
do not develop a DSM-IV use disorder; (3) incident use as well as continued use of ecstasy is 
a characteristic of adolescents and young adults. These findings indicate that use of ecstasy 
and related substances is in line with the assumption that this behavior is frequently a 
transient, ‘youth-limited’ phenomenon. While this question has been extensively discussed 
and analyzed with regard to cannabis (Chen and Kandel, 1998; Hammer and Vaglum, 1990; 
Johnston et al., 1992; Kandel and Faust, 1975; Kandel and Logan, 1984; Moffitt, 1993; 
Perkonigg et al., 1999; Silbereisen, 1997; Sydow et al., in press) this study is the first to 
analyze this with regard to ecstasy and related drugs. Spontaneous changes from use to non-
use occurred relatively often in our sample, more often as compared to the cessation of 
cannabis use. In this respect it is also noteworthy that we found no significant association that 
former users of ecstasy and related drugs compensate the cessation of their use of ecstasy by 
an increased use of other licit or illicit drugs.  
 
 
4.4. The bad news  
 
The ‘good news’ about significant rates of spontaneous cessation of 
ecstasy/stimulant/hallucinogen use in our sample is however offset by three problematic 
implications of our study.  
 
4.4.1. Increasing use of ecstasy and related substances in younger German cohorts  
 
We demonstrated a cohort effect with regard to the age of onset of use of ecstasy and related 
substances. The younger cohort (birth cohort 1977–81) tended to initiate ecstasy use at an 
earlier age than those born 1970–77.  
 
4.4.2. Ecstasy use is accompanied by an elevated use of other licit and illicit drugs  
 
Like several other researchers (Parrott et al., 2000; Schifano et al., 1998; Solowij et al., 1992; 
Thomasius, 2000; Topp et al., 1999; Tossmann, 1997), we found that ecstasy users when 
compared to non-users have significantly higher risks for use of other illicit substances like 
nicotine, cannabis, sedatives, cocaine, stimulants, hallucinogens and opiates. Although 
exusers of ecstasy and related substances tend to use less illicit drugs than continuous ecstasy-
users, they still use nicotine, cannabis, hallucinogens, cocaine, sedatives and opiates more 
often than participants who have never used ecstasy and related drugs, despite the fact that we 
did not observe ‘compensatory increases’ after discontinuation of ecstasy use.  
 
4.4.3. Existence of a high-risk group of long-time consumers of ecstasy  
 
There is a significant proportion of lifetime ecstasy users (15%) who were long-time 
consumers of ecstasy and related drugs, classified as ‘considerable’ or ‘heavy users’ before 
the 12-months preceding the last assessment (t2) and afterwards. Of these, more than one 
third fulfilled DSM-IV criteria of abuse or dependence from ecstasy and related drugs over 
more than 1 year. This subsample with long-time elevated use of ecstasy and related drugs 
and presumably of other licit and illicit drugs as well has to be considered as a problematic 
high-risk group raising clinical and public health concerns.  
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